<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542629</url>
  </required_header>
  <id_info>
    <org_study_id>CSDIMRE</org_study_id>
    <nct_id>NCT04542629</nct_id>
  </id_info>
  <brief_title>Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children</brief_title>
  <official_title>Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children Attending Assiut Pediatric University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Comparison of the efficacy of Rituximab and ketogenic diet in controlling refractory&#xD;
           seizures versus the traditional lines as corticosteroid and trace elements.&#xD;
&#xD;
        2. Improving the management of children with refractory seizures&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Definition of refractory epilepsy&#xD;
&#xD;
           A task force of the International League Against Epilepsy proposed that drug-resistant&#xD;
           epilepsy be defined as failure of adequate trials of two tolerated and appropriately&#xD;
           chosen and used antiseizure drug schedules (whether as monotherapies or in combination)&#xD;
           to achieve sustained seizure freedom (1)&#xD;
&#xD;
           . This requires application of the intervention at adequate strength/dosage for a&#xD;
           sufficient length of time (2)..Terms refractory&quot; intractable&quot;, drug-resistant&quot;&#xD;
           pharmaco-resistant&quot; have been used interchangeably in several documented literature in&#xD;
           different time periods (3). The first antiseizure drug fails in 20 to 40 percent of&#xD;
           children with epilepsy; lack of efficacy and side effects contribute to treatment&#xD;
           failure (4)&#xD;
&#xD;
           Epidemiology About 10-20 % children with epilepsy develop drug refractory epilepsy&#xD;
           (5).In a systematic review of 35 observational studies that included over 13,000&#xD;
           patients with epilepsy and 3900 patients with drug resistant epilepsy( DRE), the pooled&#xD;
           prevalence of (DRE) was 30 percent, and the pooled incidence proportion was 15 percent&#xD;
           (6).&#xD;
&#xD;
           Risk factors&#xD;
&#xD;
           - A high number of seizures prior to diagnosis and treatment&#xD;
&#xD;
           - Genetic or inherited syndromes, for both generalized and localization-related&#xD;
           epilepsy, have a better prognosis than symptomatic/cryptogenic epilepsy in both&#xD;
           pediatric and adult populations (7).&#xD;
&#xD;
             -  Localization-related epilepsy underlies more than half of the cases of DRE in&#xD;
                children (8,9).&#xD;
&#xD;
             -  Other findings more variably associated with the risk of DRE include a presentation&#xD;
                with status epilepticus , a longer duration of epilepsy , a family history of&#xD;
                epilepsy , a history of febrile convulsions , abnormal ( ELECTROENCEPHALOGRAM ) EEG&#xD;
                findings . An abnormal neurologic examination and/or developmental delays (10,11).&#xD;
&#xD;
             -  Some pediatric studies have found that seizure onset in later childhood or&#xD;
                adolescence appears to be more likely to be associated with DRE than seizures with&#xD;
                onset between the ages of 5 and 10 years (12).&#xD;
&#xD;
           Causes (13,14 ) Epilepsy syndromes&#xD;
&#xD;
           Infancy&#xD;
&#xD;
           • Epilepsy of infancy with migrating focal seizures&#xD;
&#xD;
             -  West syndrome&#xD;
&#xD;
             -  Dravet syndrome&#xD;
&#xD;
             -  Doose syndrome&#xD;
&#xD;
           Childhood&#xD;
&#xD;
             -  Lennox-Gastaut syndrome&#xD;
&#xD;
             -  Epileptic encephalopathy with continuous spike and wave during sleep&#xD;
&#xD;
           Metabolic&#xD;
&#xD;
           • Pyridoxine dependent epilepsy&#xD;
&#xD;
           • Biotinidase biosynthesis deficiency&#xD;
&#xD;
           • Organic acidemia&#xD;
&#xD;
           • Urea cycle disorders&#xD;
&#xD;
           • Non-ketotic hyperglycinemia&#xD;
&#xD;
             -  Aminoacidopathies&#xD;
&#xD;
             -  Mitochondrial disorders including Alpers syndrome&#xD;
&#xD;
             -  Hashimoto encephalopathy&#xD;
&#xD;
           Structural Abnormality&#xD;
&#xD;
           • Malformations: Neuronal migration defects and neural tube defects&#xD;
&#xD;
           • Neurocutaneous syndromes&#xD;
&#xD;
           ,&#xD;
&#xD;
           Infectious/Inflammatory:&#xD;
&#xD;
           ,&#xD;
&#xD;
           • Hypoxic ischemic encephalopathy,&#xD;
&#xD;
           • Rasmussen encephalitis&#xD;
&#xD;
             -  Stroke&#xD;
&#xD;
             -  Tumors&#xD;
&#xD;
             -  Mesial temporal sclerosis&#xD;
&#xD;
           Autoimmune epilepsies&#xD;
&#xD;
           : N-methyl-D-aspartate receptor(NMDAR),&#xD;
&#xD;
           Connective tissue disorders&#xD;
&#xD;
           • Systemic lupus erythematosus,&#xD;
&#xD;
           • Wegener's granulomatosis&#xD;
&#xD;
             -  , sarcoidsosis,&#xD;
&#xD;
             -  celiac disease,&#xD;
&#xD;
             -  Crohn's disease,&#xD;
&#xD;
             -  Behcet's&#xD;
&#xD;
             -  Sjorgren's syndrome,&#xD;
&#xD;
           EVALUATION&#xD;
&#xD;
           A- History and presentation :&#xD;
&#xD;
           The approach depends upon age of onset, accurate description: pre-ictal, ictal,&#xD;
           postictal events, precipitating events, seizure types, evolution relation to fever,&#xD;
           previous history of febrile seizures (simple/complex), associated non-epileptic events,&#xD;
           intake of (ANTI EPILPTIC DRUGS )AEDs with dose, developmental history, sleep history,&#xD;
           detailed birth and peri-/antenatal history etc.&#xD;
&#xD;
           B-Clinical examination depends upon anthropometry, syndromic facial dysmorphism,&#xD;
           neurocutaneous features and detailed neurological and systemic assessment&#xD;
&#xD;
           C- Pseudo-refractoriness indicates a condition in which seizures persist because the&#xD;
           condition has not been adequately treated. The most common causes of pseudo refractory&#xD;
           epilepsy include&#xD;
&#xD;
        1. Inappropriate diagnosis&#xD;
&#xD;
           -Cardiogenic (arrhythmias) and vasovagal events (syncope)&#xD;
&#xD;
             -  Parasomnias&#xD;
&#xD;
             -  Movement disorders (paroxysmal dyskinesias, cataplexy)&#xD;
&#xD;
             -  Psychogenic nonepileptic seizure (PNES) can mimic epileptic seizures. , do not&#xD;
                respond to antiseizure drug therapy.&#xD;
&#xD;
           While not without limitations, video-EEG monitoring is the gold standard test for the&#xD;
           diagnosis of PNES&#xD;
&#xD;
        2. Bad compliance ; Missed dose&#xD;
&#xD;
        3. Incorrect drug An incorrect diagnosis of seizure classification leading to incorrect&#xD;
           drug choice It is not uncommon for diopathic generalized epilepsy syndromes to be&#xD;
           unrecognized and inappropriately treated with antiseizure drugs that are more&#xD;
           appropriate to localization-related epilepsy .&#xD;
&#xD;
        4. Inadequate dosage&#xD;
&#xD;
        5. Inadequate frequency&#xD;
&#xD;
        6. Enzyme induction, especially if more than one antiepilptic drug AED or other medication&#xD;
           is used&#xD;
&#xD;
        7. Inadequate anticonvulsant therapy&#xD;
&#xD;
      D-Investigation for the patients include;&#xD;
&#xD;
      1-EEG Routine EEG is a must for the clinical diagnosis of epilepsy and associated syndrome.&#xD;
&#xD;
      For the majority of patients with epilepsy, routine EEG is sufficient to classify seizure&#xD;
      type and to start treatment But for refractory epilepsy ( RE) and a doubtful seizure,&#xD;
      video-EEG monitoring is the best diagnostic tool available. 2-Drug level monitor 3-Serum&#xD;
      electrolyte, serum glucose 4-MRI brain ; High-resolution MRI helps in isolating the cause of&#xD;
      focal epilepsies and to predict long-term outcome and spontaneous remission in patients. In&#xD;
      some cases, follow-up MRI reveals an etiology for epilepsy (such as cerebral neoplasm,&#xD;
      autoimmune encephalitis) that was not seen on the initial study and requires specific&#xD;
      therapies in addition to antiseizure drugs . 5- Metabolic Work up Arterial blood gas (ABG )&#xD;
      Serum ammonia ,lactate Tandem mass screening 6-Genetic Testing as karyotyping , gene sequence&#xD;
      ,-Fundus examination The presence of features like dysmorphism, growth retardation,&#xD;
      intellectual disability and hypotonia may indicate an underlying genetic syndrome, 7-CSF&#xD;
      culture, analysis • Lumbar puncture of infectious process 8-vascuilitis panel Complete blood&#xD;
      cell count Erythrocyte sedimentation rate CRP ( C REACTIVE PROTEIN ) VWF Ag (VON WILLEBRAND&#xD;
      FACTOR) C 3, 4 (COMPLEMENT 3, 4) Antinuclear AB (ANTIBODY) Antiphospholipid AB Antineutrophil&#xD;
      cytoplasmic AB Anti-DNA AB 9-autoimmune encephalitis (Hashimotos ) antithyroid peroxidase AB,&#xD;
      anti-TSH receptor AB Anti-NMDA-R AB Anti-MOG AB (if CNS demyelination) abdominal ultrasound&#xD;
      and -MRI abdomen;To detect ovarian teratoma as in autoimmune encephalitis&#xD;
&#xD;
      F-Practice recommendations for AED trial:&#xD;
&#xD;
        1. Optimise the dose of each AED by increasing the dose incrementally. If the maximum dose&#xD;
           is ineffective introduce a second AED while continuing on the first. If seizure control&#xD;
           is achieved, consider tapering the first AED. The advice to &quot;start low and go slow&quot; is&#xD;
           appropriate 2. If one or two AEDs are ineffective, rational polytherapy should be&#xD;
           explored. 3. Consider using AEDs with different mechanisms of action 4. Avoid using an&#xD;
           AED that may worsen or provoke seizures Carbamazepine (CBZ), Oxcarbazepine (OXC),&#xD;
           Phenytoin (PHT), Vigabatrin (VGB) and Tiagabine (TGB) may worsen myoclonus and absence&#xD;
           seizures&#xD;
&#xD;
             -  Gabapentin (GBP) and Lamotrigine (LTG) may worsen myoclonus (Benzodiazepines given&#xD;
                intravenously may worsen tonic seizures but may be very useful in treating&#xD;
                Lennox-Gastaut and does not contraindicate their use&#xD;
&#xD;
           Background A-Immunotherapy&#xD;
&#xD;
           Evidence that the immune system is involved in the pathogenesis of epilepsy&#xD;
           particularly, medically refractory epilepsy, has given rise to the use of adjunctive&#xD;
           immunotherapy to slow or change the epileptogenic process.&#xD;
&#xD;
             -  The presumed immune therapeutic mechanism (ACTH, corticosteroids, plasmapheresis&#xD;
                human immunoglobulin G, rituximab, azathioprine, and cyclophosphamide) is the&#xD;
                removal of various neuroimmunological mechanisms involved. However, new models&#xD;
                suggest suppression of endogenous brain agent's proconvulsant (neuropeptides) There&#xD;
                is limited data of these treatments outside of specific epileptic encephalopathies&#xD;
                such as West syndrome, Rasmussen encephalitis, Landau Kleffner and specific&#xD;
                antibody mediated encephalitis such as anti NMDA encephalitis a) Corticosteroids:&#xD;
                Their immunological mechanisms are inhibition diapedesis and therefore infiltration&#xD;
                of lymphocytes to the injured areas, attenuating production of inflammatory humoral&#xD;
                mediators (IL-2) and inhibition of leukocyte function (helper T lymphocytes mainly)&#xD;
                as well as endothelial cells.&#xD;
&#xD;
           Dose:&#xD;
&#xD;
           Methylprednisolone 30 mg /kg /day for 5 days up to 1 gm /day ,pulsed monthly for 6&#xD;
           months (15).&#xD;
&#xD;
           b) Plasmapheresis: the activity of auto-Abs can be modulated by treatment with IVIGs and&#xD;
           by plasma treatment, which consists of the mechanical removal of Abs (16)&#xD;
&#xD;
           c) Human immunoglobulin G:&#xD;
&#xD;
           . IgGIV inhibits activation of innate cells, suppression of the production of&#xD;
           proinflammatory cytokines, and soluble factors as tumor necrosis factor and interleukins&#xD;
           induced by this factor. In endothelial cells and macrophages, suggesting a mechanism&#xD;
           antiepileptic Dose:400 mg.kg /day for 5 days&#xD;
&#xD;
           D--Rituximab:&#xD;
&#xD;
           Rituximab, a chimeric monoclonal antibody that binds to CD20, was the first monoclonal&#xD;
           antibody to be approved for clinical use in the therapy of cancer. It is approved for&#xD;
           use against indolent B-cell non-Hodgkin's lymphoma (NHL), although its use has expanded&#xD;
           significantly beyond that indication to virtually any CD20-positive NHL, and more&#xD;
           recently into other areas such as autoimmune disorders&#xD;
&#xD;
           ) Rituximab targets CD20, a transmembrane protein present on virtually all B cells from&#xD;
           the stage at which they become committed to B-cell development until it is downregulated&#xD;
           when they differentiate into antibody-secreting plasma cells (17) Numerous review&#xD;
           articles whose primary focus is the action of rituximab in the treatment of RA, systemic&#xD;
           lupus erythematosus (SLE) and other autoimmune diseases were published in 2006. Although&#xD;
           there is a clear consensus that substantial clinical benefits are associated with&#xD;
           rituximab therapy, the exact mechanism(s) by which the B-cell depletion promoted by&#xD;
           rituximab ameliorates autoimmune disease activity remains an area of active&#xD;
           discussion.(18, 19) The most likely mechanisms have naturally centered on the pathogenic&#xD;
           role of B cells in autoimmune disease: these include the potential of B cells to give&#xD;
           rise to plasma cells that secrete autoantibodies as well as the ability of&#xD;
           autoantigen-specific B cells to present antigens to autoreactive T cells, which leads to&#xD;
           T-cell activation, cytokine release and inflammation. In certain cases the results of&#xD;
           clinical trials have demonstrated moderate correlations between reduction of&#xD;
           autoantibody levels and lessening of disease symptoms, which has emphasized the role of&#xD;
           autoantibodies in disease pathology. In other studies such correlations have not been&#xD;
           observed, which has led investigators to favor B cell-T cell interactions as the most&#xD;
           important in the etiology of tissue injury in autoimmune diseases.&#xD;
&#xD;
      (20 ,21)&#xD;
&#xD;
      B-Dietary Therapy&#xD;
&#xD;
        1. ketogenic diet rationale; The common element of these different approaches is variable&#xD;
           reduction in the amount of carbohydrate with appropriate increase in fat.&#xD;
&#xD;
           Diets that produce a state of ketosis are referred to as ''ketogenic&quot; When deprived of&#xD;
           glucose through restriction of carbohydrate intake, the human body begins metabolizing&#xD;
           fat.In doing so, ketone bodies (acetoacetate, acetone, and hydroxybutyrate) are produced&#xD;
           . (22).&#xD;
&#xD;
           KDT is associated with increased mitochondrial biogenesis, oxidative phosphorylation,&#xD;
           enhanced gamma-aminobutyric acid (GABA) levels, reduced neuronal excitability and&#xD;
           firing, and stabilized synaptic function (23)&#xD;
&#xD;
           Indicated Dietary therapy has been reported as effective in the treatment of seizures&#xD;
           associated with glucose transporter 1 deficiency, pyruvate dehydrogenase deficiency,&#xD;
           infantile spasms, absence epilepsy, myoclonic atonic epilepsy (Doose syndrome), Dravet&#xD;
           syndrome, tuberous sclerosis complex, mitochondrial disorders, Lennox-Gastaut syndrome,&#xD;
           Sturge-Weber syndrome, and Rett syndrome (24) Results from the randomized control trial&#xD;
           indicated that 38% of children had more than 50% reduction in seizure frequency, and 7%&#xD;
           had more than 90% reduction in seizure frequency three months after starting classic&#xD;
           ketogenic diet. Retrospective studies reported a higher rate of seizure control (25).&#xD;
&#xD;
           Contraindications Absolute contraindications for the use of diet therapy include&#xD;
           carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II deficiency,&#xD;
           carnitine translocase deficiency, β-oxidation defects, pyruvate carboxylase deficiency,&#xD;
           and porphyria.&#xD;
&#xD;
        2. trace elements and antioxidants; The equilibrium of trace elements is essential for a&#xD;
           healthy nervous system due to their key roles in activation of specific enzyme in many&#xD;
           pathways of the central nervous system function metabolism&#xD;
&#xD;
             -  Essential trace elements that include zinc, copper, magnesium, and selenium might&#xD;
                play a role in the pathogenesis of seizures because of their possible influence on&#xD;
                synaptogenesis, their actions on ligand- and voltage-gated ion channels, their&#xD;
                effects on membrane lipid peroxidation and turnover of some neurotransmitters, and&#xD;
                their roles in immunity (26)&#xD;
&#xD;
      Antioxidative defense mechanisms are important pathways involving trace elements. The&#xD;
      accumulation of free radicals may lead to seizures and increases the risk o f their&#xD;
      recurrence, because oxidative stress produces peroxidated membrane lipids and damages the&#xD;
      cells&#xD;
&#xD;
      . Glutathione peroxidase (GPx) and superoxide dismutase (SOD) are two major enzymes that are&#xD;
      involved in antioxidative defense mechanisms.&#xD;
&#xD;
      Selenium (Se), zinc (Zn), and copper (Cu) are important trace elements that participate in&#xD;
      the structure of these enzymes patients with intractable epilepsy had significantly decreased&#xD;
      levels of serum Se and Zn in comparison to the controlled group(27)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a-seizure frequency b-antiepileptic drugs c-compliance to treatment d-number of hospital admission</measure>
    <time_frame>1 YEAR</time_frame>
    <description>number of attacks of fits during monitoring</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>RITUXIMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KETOGENIC DIET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.&#xD;
Diets that produce a state of ketosis are referred to as ''ketogenic&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRACE ELEMENTS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>. Essential trace elements that include zinc, copper, magnesium, and selenium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CORTICOSTEROID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RiTUXimab Injection [Rituxan]</intervention_name>
    <description>375 MG/M2 /WEEK INFUSION</description>
    <arm_group_label>CORTICOSTEROID</arm_group_label>
    <arm_group_label>KETOGENIC DIET</arm_group_label>
    <arm_group_label>RITUXIMAB</arm_group_label>
    <arm_group_label>TRACE ELEMENTS</arm_group_label>
    <other_name>KETOGENIC DIET</other_name>
    <other_name>TRACE ELEMENTS</other_name>
    <other_name>CORTICOSTEROID INJECTION</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1-Age 1 month up to 17 years 2-Both male and female 3-Epileptic patient on two&#xD;
             tolerated and appropriately chosen and used antiepilptic drugs with no response&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1-Neonate 2-Epieptic patient on monotherapy 3-Conditions mimic epilepsy 4-Pseudo&#xD;
             refractioness 5-Absolute contraindications for the use of diet therapy include&#xD;
             carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II&#xD;
             deficiency, carnitine translocase deficiency, β-oxidation defects, pyruvate&#xD;
             carboxylase deficiency, and porphyria 6-Contraindication for Rituximab:&#xD;
&#xD;
               1. Hypersensitivity to any component, murine proteins. b. Heart failure c. Active&#xD;
                  infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad eldeen Mahmoud Hammad, professor</last_name>
    <role>Study Director</role>
    <affiliation>aAssiut University Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duaa Mohammad Raafat Mahmoud, professor</last_name>
    <phone>01223112124</phone>
    <email>duaa-raafat@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahlam Badawy Ali Badawy, assisstant professor</last_name>
    <phone>01006807866</phone>
    <email>dr.ahlam_ali@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </reference>
  <reference>
    <citation>Beleza P. Refractory epilepsy: a clinically oriented review. Eur Neurol. 2009;62(2):65-71. doi: 10.1159/000222775. Epub 2009 Jun 12. Review.</citation>
    <PMID>19521080</PMID>
  </reference>
  <reference>
    <citation>Aneja S, Jain P. Refractory epilepsy in children. Indian J Pediatr. 2014 Oct;81(10):1063-72. doi: 10.1007/s12098-014-1533-1. Epub 2014 Aug 9. Review.</citation>
    <PMID>25106842</PMID>
  </reference>
  <reference>
    <citation>Dudley RW, Penney SJ, Buckley DJ. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol. 2009 Feb;40(2):71-7. doi: 10.1016/j.pediatrneurol.2008.09.021.</citation>
    <PMID>19135617</PMID>
  </reference>
  <reference>
    <citation>Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec;59(12):2179-2193. doi: 10.1111/epi.14596. Epub 2018 Nov 13.</citation>
    <PMID>30426482</PMID>
  </reference>
  <reference>
    <citation>Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia. 2006 Feb;47(2):431-6.</citation>
    <PMID>16499772</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.</citation>
    <PMID>10660394</PMID>
  </reference>
  <reference>
    <citation>Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology. 2001 Dec 26;57(12):2259-64.</citation>
    <PMID>11756607</PMID>
  </reference>
  <reference>
    <citation>Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology. 2001 Jun 12;56(11):1445-52. Erratum in: Neurology 2001 Sep 11;57(5):939.</citation>
    <PMID>11402099</PMID>
  </reference>
  <reference>
    <citation>Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol. 2001 Oct;58(10):1543-6. Review.</citation>
    <PMID>11594910</PMID>
  </reference>
  <reference>
    <citation>Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012 May 15;78(20):1548-54. doi: 10.1212/WNL.0b013e3182563b19. Epub 2012 May 9.</citation>
    <PMID>22573629</PMID>
  </reference>
  <reference>
    <citation>Nikodijevic D, Baneva-Dolnenec N, Petrovska-Cvetkovska D, Caparoska D. Refractory Epilepsy-MRI, EEG and CT scan, a Correlative Clinical Study. Open Access Maced J Med Sci. 2016 Mar 15;4(1):98-101. doi: 10.3889/oamjms.2016.029. Epub 2016 Feb 16.</citation>
    <PMID>27275339</PMID>
  </reference>
  <reference>
    <citation>Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435-45.</citation>
    <PMID>7506951</PMID>
  </reference>
  <reference>
    <citation>Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7. Review.</citation>
    <PMID>16932648</PMID>
  </reference>
  <reference>
    <citation>Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005 Sep;17(5):550-7. Review.</citation>
    <PMID>16093832</PMID>
  </reference>
  <reference>
    <citation>Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006 May;6(5):394-403. Review.</citation>
    <PMID>16622478</PMID>
  </reference>
  <reference>
    <citation>Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):756-66. doi: 10.1212/01.CON.0000431396.23852.56. Review.</citation>
    <PMID>23739109</PMID>
  </reference>
  <reference>
    <citation>Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007 Jan;48(1):43-58. Review.</citation>
    <PMID>17241207</PMID>
  </reference>
  <reference>
    <citation>Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol. 2009 Aug;24(8):979-88. doi: 10.1177/0883073809337162. Epub 2009 Jun 17. Review.</citation>
    <PMID>19535814</PMID>
  </reference>
  <reference>
    <citation>Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.</citation>
    <PMID>18456557</PMID>
  </reference>
  <reference>
    <citation>Yuen AW, Sander JW. Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Res. 2012 Jun;100(1-2):152-6. doi: 10.1016/j.eplepsyres.2012.02.004. Epub 2012 Mar 8. Review.</citation>
    <PMID>22406257</PMID>
  </reference>
  <reference>
    <citation>Hayashi M. Oxidative stress in developmental brain disorders. Neuropathology. 2009 Feb;29(1):1-8. doi: 10.1111/j.1440-1789.2008.00888.x.</citation>
    <PMID>19154320</PMID>
  </reference>
  <reference>
    <citation>Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology. 2004 Mar 9;62(5):708-13.</citation>
    <PMID>15007118</PMID>
  </reference>
  <reference>
    <citation>van Mierlo P, Carrette E, Hallez H, Raedt R, Meurs A, Vandenberghe S, Van Roost D, Boon P, Staelens S, Vonck K. Ictal-onset localization through connectivity analysis of intracranial EEG signals in patients with refractory epilepsy. Epilepsia. 2013 Aug;54(8):1409-18. doi: 10.1111/epi.12206. Epub 2013 May 3.</citation>
    <PMID>23647147</PMID>
  </reference>
  <reference>
    <citation>Salmenpera TM, Symms MR, Rugg-Gunn FJ, Boulby PA, Free SL, Barker GJ, Yousry TA, Duncan JS. Evaluation of quantitative magnetic resonance imaging contrasts in MRI-negative refractory focal epilepsy. Epilepsia. 2007 Feb;48(2):229-37.</citation>
    <PMID>17295615</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Nancy Alaa</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trace Elements</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

